![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Baseline HCV NS5A Resistance-Associated Variants Do Not Impact SVR12 Rates in Non-Cirrhotic and Post-Liver Transplant Patients With Genotype 1 Infection Treated With Daclatasvir and Sofosbuvir With or Without Ribavirin for 12 Weeks: An Integrated Analysis
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco, CA
McPhee F,1 Hernandez D,1 Zhou N,1 Ueland J,1 Vellucci V,1 Hartman-Neumann S,1 Yang X,1 Han Z,1 Yu F,1 Yang R,2 Noviello S2
1Bristol-Myers Squibb Research and Development, Wallingford, CT; 2Bristol-Myers Squibb Research and Development, Princeton, NJ
![AASLD1.gif](../images/111815/111815-9/AASLD1.gif)
![AASLD2.gif](../images/111815/111815-9/AASLD2.gif)
![AASLD3.gif](../images/111815/111815-9/AASLD3.gif)
![AASLD4.gif](../images/111815/111815-9/AASLD4.gif)
![AASLD5.gif](../images/111815/111815-9/AASLD5.gif)
![AASLD6.gif](../images/111815/111815-9/AASLD6.gif)
![AASLD7.gif](../images/111815/111815-9/AASLD7.gif)
![AASLD8.gif](../images/111815/111815-9/AASLD8.gif)
![AASLD9.gif](../images/111815/111815-9/AASLD9.gif)
![AASLD10.gif](../images/111815/111815-9/AASLD10.gif)
![AASLD11.gif](../images/111815/111815-9/AASLD11.gif)
![AASLD12.gif](../images/111815/111815-9/AASLD12.gif)
![AASLD13.gif](../images/111815/111815-9/AASLD13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|